Experts discuss the current research on the use of digital therapeutics for managing chronic pain in rheumatic disease.

The Food and Drug Administration (FDA) has approved Journavx™ (suzetrigine) for the treatment of moderate to severe acute pain in adults.

The lived experience of severe pain, understandably, can lead to a process of catastrophizing, which is a cognitive distortion where patients assume the worst possible outcome in any situation where ...

The encouraging result comes just days after the US FDA approved Vertex Pharma's non-opioid painkiller Journavx (suzetrigine) ...

Accurate pain reporting in sickle cell disease is critical to effective pain assessment and management, but accuracy depends on patient comprehension of forms.

Patients with and without obesity experienced significant pain reductions and improved functioning following telerehabilitation for chronic musculoskeletal pain.

The greenlight for Journavx (suzetrigine), which comes on the heels of a $7.4 billion opioid settlement, could spark momentum ...

Pleasure and pain are important factors in how we humans make decisions. So why not give artificial intelligence a taste of it as well? I could think of a few reasons, but a team from Google, DeepMind ...

The following is a summary of “Pain Assessment and Management in Oncological Practice: A Survey from the Italian Network of Supportive Care in Oncology,” published in the January 2025 issue of Pain by ...

Tris Pharma has reported positive outcomes from its ALLEVIATE-1 Phase III trial of cebranopadol to treat moderate-to-severe ...